Expressions of Interest, Group Leader in Cardiovascular Disease
Monash is a dynamic internationally competitive university ranked in the world's top 100. It is a member of the prestigious Group of Eight research-intensive Australian universities, and the international M8 Alliance of Academic Health Centres and Medical Universities.
Monash prides itself on providing a world-class environment for biomedical research; promoting an interdisciplinary, collaborative research community underpinned by outstanding research facilities. Monash has recently created a new Biomedicine Discovery Institute (BDI) at the Clayton Campus to create strengths in a number of global health priority fields, including Cardiovascular Disease.
The focus of the BDI Cardiovascular Disease program is to pursue excellence in discovery research and to inform on the basic principles of the cardiovascular system from cell biology through to organ systems, with potential for translation through collaborations with clinical partners. The excellence of Cardiovascular research at Monash has been recognised by award of the highest ranking classification (5; "well above world standard") by the Australian Government in the ERA (Excellence in Research) assessment. Cardiovascular researchers at the BDI benefit from access to world-class research platforms as well as affiliated clinical sites and the Australian Regenerative Medicine Institute (ARMI).
For more detailed information on the Monash Biomedicine Discovery Institute please visit monash.edu/discovery-institute
Expressions of interest are sought from emerging or established leaders in the field of Cardiovascular Disease to establish independent laboratories or to relocate their existing laboratories to this vibrant and expanding environment within Monash University. Opportunities for collaboration with existing research laboratories in the field will be promoted and encouraged.
Applicants must have a track record in high-impact research and success in competitive grant funding, judged relative to their stage of career along with an outstanding publication record of quality peer reviewed science. Applications from researchers with expertise in integrative cardiovascular disease models, fibrosis biology, vascular biology and atherosclerosis, and cardiopulmonary pharmacology will be particularly welcome in the current round.
The successful candidates will be offered attractive start-up packages and excellent benefits and conditions of employment.
Submissions and Enquiries
All enquiries will be held in strict confidence.
Contact: Professor Robert Widdop, firstname.lastname@example.org
Sunday 1 January 2017, 11.55pm AEDT